Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU

PE-PE is a fantastic study, giving us randomized data on adding pembrolizumab to MDT in oligometastatic RCC! Phase II, open-label, multicenter trial: 85 pts with prior nephrectomy and ≤3 mets within 5y of nephrectomy or previous metastasectomy, all amenable to surgery or SABR. Randomized 2:1 favoring pembro: MDT alone (n=29) vs pembro + MDT (n=56). Pembro 400 mg q6w x9c (1y). First dose BEFORE MDT; registry specifies MDT on C1d21-42. At MFU 17.5 mo, median RFS was 11→ 25.4 mo (HR 0.47, 95CI 0.24-0.92, p=0.024), MDT alone→ pembro + MDT. 35 RFS events, 16→ 19. SABR 72→ 73%; surgery 28→ 23%. SABR dose/fx and per-site data weren't reported. I'd like to see those details along with local vs distant relapse. Any AE 21→ 80%; G3 AEs 3→ 7%. The 21% control rate is with no study systemic therapy. Pembro-related AEs occurred in 59%, including G3 in 2 pts; no G4/5 pembro-related events were reported. Four pts stopped pembro for AEs. Both groups received MDT, so the randomized question is what pembro adds. This doesn't establish the benefit of MDT itself or RT-ICI synergy. With 1 death/arm and no QoL results reported, an OS/QoL benefit remains unestablished. I'd also like the prior systemic therapy history and the timing/burden at first metastatic presentation. The eligibility window alone doesn't tell us whether these pts were oligometastatic from the outset. Congratulations to the investigators on this important work! cslide.ctimeetingtech.com/es… #radonc #ESMO26 #RCC

Bladder preservation after neoadjuvant/perioperative therapy in 🇮🇹 MIBC pts who declined RC and underwent reTURBT (n=54) 📌Negative imaging, biopsy & cytology 🔹19% recurred; 13% developed distant recurrence 🔹 ypT0Nx at reTURBT → 24-mo EFS 88%; MFS & OS >95%, comparable with ypT0N0 after RC 🔹 Residual disease at reTURBT → substantially worse vs non-pCR after RC: 24-mo EFS 19% vs 68%; OS 50% vs 83% 🔹 20% required delayed RC or chemoRT 🔹 Baseline cT3–4 disease also associated with poorer outcomes 🔑 Pathologic clearance at reTURBT may identify a highly selected group for bladder preservation; residual disease was associated with markedly inferior outcomes vs RC. @urotoday #ESMO26